Monday, July 27, 2009

Hybrid A/H1N1 flu tied to genetic trigger for larger, mutated version

By Wayne Madsen
Online Journal Contributing Writer
Jun 24, 2009, 00:17

(WMR) -- WMR previously reported on the genetic manipulation of the 1918 flu from tissue extracted from an Inuit woman who died from the pandemic in Alaska. On May 6, WMR reported: “WMR has obtained information from biological researchers that the 1918 Spanish flu genetic sequences were ‘manipulated’ in order to effect transmission capability.

The current H1N1 virus, called ‘swine flu,’ is reportedly a combination of two forms of human flu, two forms of swine flu (North American and Eurasian), and avian or bird flu . . . Two bio-safety laboratories have been associated with the genetic reverse engineering of not only A-H1N1, the current ‘swine flu’ strain, but also the deadly Ebola virus. They are the University of Wisconsin-Madison and the National Microbiology Laboratory in Winnipeg, Canada.”

WMR has now learned from virus researchers that the current A-H1N1 strain strongly appears tied to vaccinations for the seasonal form on influenza. The hybrid flu began in countries where seasonal vaccinations are commonplace and where A-H1N1 did not respond to the normal seasonal flu vaccination antibody, according to researchers studying the new virus.

What has some researchers alarmed is that the engineers of A-H1N1 purposely planned to make the virus non-responsive to any available vaccine. There is also a suspicion by researchers that the A-H1N1 vaccine under development will trigger a more deadly mutated form of the virus for which the A-H1N1 vaccine will be ineffective.

On May 19, WMR reported: “What researchers have told us is that as long as the current AH1N1 can infect humans, it will not try to mutate. Even though there have been deaths from AH1N1, most of those infected are sick for up to four days, take Tamiflu or similar drugs, and recover with immunity from the hybrid or ‘novel’ virus . . . However, with vaccinations, the AH1N1 virus will, of course, be rejected by human hosts and cases around the world will decrease. However, then, the virus will begin to mutate in order to successfully infect human hosts. And when that happens, the new, newly-mutated virus will become much more transmissible and more pathogenic. The nightmare scenario is that the new, mutated virus may take on the characteristics of H5N1 or the avian flu. The vaccines administered for AH1N1 will be ineffective against the new strain of H5N1 and the world may face a more deadly pandemic then the current AH1N1 outbreak. There are scientists at WHO who are aware of this scenario but their alarm has been suppressed by political and economic considerations.”

Public health officials in Brazil are reporting that the A/H1N1 virus is now in the process of mutating, confirming our earlier reports. A new variant of the pandemic virus is showing up in patients in Brazil making treatment more difficult.

On May 13, 2009, WMR reported: “Because of the rapid mutation of the virus and the fact that, unlike 1918, rapid global transportation is now the norm, scientists are predicting that the molecular clock of the A/H1N1 virus, coupled with modern transportation, means that almost all the countries of the world will experience an A/H1N1 outbreak within the next few months.”

The prediction about the rate of global infection is being borne out by reports of the virus now being reported in many more nations, including South Africa, Yemen, Qatar, India, and Morocco, as well as uncontained surges in Australia, New Zealand, the UK, Utah, and Argentina.

In another suspicious turn of events, Ivorian national Konan Yao, a former researcher at the Winnipeg laboratory that has been involved in A/H1N1 research and who was arrested by the FBI at the U.S. border crossing on May 5 trying to sneak 22 vials of Ebola and HIV genetic material into the United States for his new job at the National Institutes of Health in Bethesda, Maryland, near Washington, DC, was given his post-plea bargain sentence in federal court in Grand Forks, North Dakota, late last month: 17 days in prison which equated to time served and a $500 fine. Yao’s federal charge was “failure to present merchandise for inspection,” a lesser charge from the original “attempting to bring biological material into the United States without a permit.” Yao’s new job was at the NIH’s Biodefense Research Laboratory.

The federal prosecutor who cut the plea deal with Yao is Lynn Jordheim, the assistant U.S. attorney in Fargo, who also happens to be the U.S. Attorney’s office representative on the Anti-terrorism Advisory Council (ATAC) and Crisis Management Coordinator for the federal jurisdiction and, more intriguing, the “Confidential Human Source Coordinator.”